Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the co-development and commercialization of the first-in-class radioenhancer, with the development plan initially focused on cancers of the head, neck, and lungs. The company took a non-dilutive strategic royalty monetization with HCRx, saw continued advancement of the JNJ-1900 (NBTXR3) program with completion of the Phase 3 head and neck cancer study sponsorship transfer to J&J, and its Curadigm Nanoprimer program is rapidly emerging as a long-term growth driver.
Cyborg Score Rationale
Nanobiotix has a market cap of $1.502B with revenue of $10.16M (trailing twelve months) and cash position of $28.82M as of February 27, 2026. The company has secured up to $71M in non-dilutive financing and has multiple Phase 1 clinical data readouts expected in 2026. However, the company is pre-commercial with negative earnings and relies on clinical trial outcomes.
Top Insights
Guggenheim raised their price target on Nanobiotix from $8.00 to $26.00 with a 'buy' rating as of February 6th, 2026.
The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix is the owner of more than 25 patent families associated with three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system.
The company achieved projected cash visibility into early 2028 assuming receipt of HCRx funds, providing extended runway for clinical development.
Named Competitors
Radiotherapy Enhancement — Clinical-stage oncology company (Market Cap: $1.078B)
(February 2026) Nanobiotix announced management participation in multiple March 2026 investor conferences including TD Cowen's Health Care Conference, UBS Biotech Summit, Jefferies Biotech on the Beach, and Leerink's Global Healthcare Conference.
(November 2025) Nanobiotix reported closing of its non-dilutive royalty financing transaction with HCRx with clinical updates from ongoing JNJ-1900 Phase 1 studies in melanoma, lung cancer, pancreatic cancer, and esophageal cancer expected in 2026.
(March 2026) The stock traded as high as $31.62 and reached a new 52-week high, representing significant momentum in early March 2026.
Open the full interactive Nanobiotix S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.